̽��ֱ�� of Cambridge - Early Cancer Institute

Scientists create 'metal detector' to hunt down tumours

cjb250 — Thu, 10 Apr 2025 09:00:56 +0000

In a paper published today in Nature Genetics, scientists at the ̽��ֱ�� of Cambridge and NIHR Cambridge Biomedical Research Centre analysed the full DNA sequence of 4,775 tumours from seven types of cancer. They used that data from Genomics England’s 100,000 Genomes Project to create an algorithm capable of identifying tumours with faults in their DNA that makes them easier to treat.

̽��ֱ��algorithm, called PRRDetect, could one day help doctors work out which patients are more likely to have successful treatment. That could pave the way for more personalised treatment plans that increase people’s chances of survival.

̽��ֱ��research was funded by Cancer Research UK and the National Institute for Health and Care Research (NIHR).

Professor Serena Nik-Zainal from the Early Cancer Institute at the ̽��ֱ�� of Cambridge, lead author of the study, said: “Genomic sequencing is now far faster and cheaper than ever before. We are getting closer to the point where getting your tumour sequenced will be as routine as a scan or blood test.

“To use genomics most effectively in the clinic, we need tools which give us meaningful information about how a person’s tumour might respond to treatment. This is especially important in cancers where survival is poorer, like lung cancer and brain tumours.

“Cancers with faulty DNA repair are more likely to be treated successfully. PRRDetect helps us better identify those cancers and, as we sequence more and more cancers routinely in the clinic, it could ultimately help doctors better tailor treatments to individual patients.”

̽��ֱ��research team looked for patterns in DNA created by so-called ‘indel’ mutations, in which letters are inserted or deleted from the normal DNA sequence.

They found unusual patterns of indel mutations in cancers that had faulty DNA repair mechanisms – known as ‘post-replicative repair dysfunction’ or PRRd. Using this information, the scientists developed PRRDetect to allow them to identify tumours with this fault from a full DNA sequence.

PRRd tumours are more sensitive to immunotherapy, a type of cancer treatment that uses the body’s own immune system to attack cancer cells. ̽��ֱ��scientists hope that the PRRd algorithm could act like a ‘metal detector’ to allow them to identify patients who are more likely to have successful treatment with immunotherapy.

̽��ֱ��study follows from a previous ‘archaeological dig’ of cancer genomes carried out by Professor Nik-Zainal, which examined the genomes of tens of thousands of people and revealed previously unseen patterns of mutations which are linked to cancer.

This time, Professor Nik-Zainal and her team looked at cancers which have a higher proportion of tumours with PRRd. These include bowel, brain, endometrial, skin, lung, bladder and stomach cancers. Whole genome sequences of these cancers were provided by the 100,000 Genomes Project - a pioneering study led by Genomics England and NHS England which sequenced 100,000 genomes from around 85,000 NHS patients affected by rare diseases or cancer.

̽��ֱ��study identified 37 different patterns of indel mutations across the seven cancer types included in this study. Ten of these patterns were already linked to known causes of cancer, such as smoking and exposure to UV light. Eight of these patterns were linked to PRRd. ̽��ֱ��remaining 19 patterns were new and could be linked to causes of cancer that are not fully understood yet or mechanisms within cells that can go wrong when a cell becomes cancerous.

Executive Director of Research and Innovation at Cancer Research UK, Dr Iain Foulkes, said: “Genomic medicine will revolutionise how we approach cancer treatment. We can now get full readouts of tumour DNA much more easily, and with that comes a wealth of information about how an individual’s cancer can start, grow and spread.

“Tools like PRRDetect are going to make personalised treatment for cancer a reality for many more patients in the future. Personalising treatment is much more likely to be successful, ensuring more people can live longer, better lives free from the fear of cancer.”

NIHR Scientific Director, Mike Lewis, said: “Cancer is a leading cause of death in the UK so it's impressive to see our research lead to the creation of a tool to determine which therapy will lead to a higher likelihood of successful cancer treatment.”

Chief Scientific Officer at Genomics England, Professor Matt Brown, said: “Genomics is playing an increasingly important role in healthcare and these findings show how genomic data can be used to drive more predictive, preventative care leading to better outcomes for patients with cancer.

“ ̽��ֱ��creation of this algorithm showcases the immense value of whole genome sequencing not only in research but also in the clinic across multiple diverse cancer types in advancing cancer care.”

̽��ֱ�� ̽��ֱ�� of Cambridge is fundraising for a new hospital that will transform how we diagnose and treat cancer. Cambridge Cancer Research Hospital, a partnership with Cambridge ̽��ֱ�� Hospitals NHS Foundation Trust, will treat patients across the East of England, but the research that takes place there promises to change the lives of cancer patients across the UK and beyond. Find out more here.

Reference

Koh, GCC et al. Redefined indel taxonomy reveals insights into mutational signatures. Nat Gen; 10 Apr 2025; DOI:

Adapted from a press release from Cancer Research UK

Cambridge researchers have created a ‘metal detector’ algorithm that can hunt down vulnerable tumours, in a development that could one day revolutionise the treatment of cancer.

Genomic sequencing is now far faster and cheaper than ever before. We are getting closer to the point where getting your tumour sequenced will be as routine as a scan or blood test

Professor Serena Nik-Zainal

̽��ֱ�� of Cambridge

Serena Nik-Zainal at the Early Cancer Institute

̽��ֱ��text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright © ̽��ֱ�� of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Licence type:

Attribution

Under the bonnet at Dawn, the UK's fastest AI supercomputer

hcf38 — Mon, 17 Mar 2025 15:58:08 +0000

How AI supercomputer, Dawn, is being used to tackle some of the most pressing issues facing humanity.

Cambridge Festival celebrates pioneering women for International Women’s Day

zs332 — Fri, 07 Mar 2025 10:28:52 +0000

For International Women’s Day (8 March), the Cambridge Festival (19 March – 4 April) is celebrating some of the remarkable contributions of women across diverse fields. From philosophy and music to AI and cosmology, the festival will highlight the pioneering work of women who have shaped our understanding of the world in profound ways.

Cambridge researchers develop urine test for early detection of lung cancer

Anonymous — Fri, 06 Dec 2024 05:49:55 +0000

Researchers hope that early detection, through the simple urine test, could enable earlier treatment interventions, significantly improving patient outcomes and prognosis. Around 36,600 lives are saved from lung cancer in the UK every year, according to new analysis from Cancer Research UK.

Professor Ljiljana Fruk and Dr Daniel Munoz Espin and their teams at the ̽��ֱ�� of Cambridge are leading on the research, funded by Cancer Research UK.

̽��ֱ��work, at Cambridge’s Department of Chemical Engineering and Biotechnology, and the Early Cancer Institute, will provide a cheap, affordable sensor that uses urine samples to help doctors detect lung cancer before the disease develops.

Lung cancer has a poor prognosis for many patients because often there are no noticeable symptoms until it has spread through the lungs or into other parts of the body. ̽��ֱ��new urine test will allow doctors to spot the disease before it develops.

To create the test, scientists looked at proteins excreted by senescent cells: “zombie” cells which are alive but unable to grow and divide. It’s these cells that cause tissue damage by reprogramming their immediate environment to help promote the emergence of cancer cells.

Now, researchers have developed an injectable sensor that interacts with zombie cell proteins and releases easily detectable compound into urine, signalling their presence.

“Early detection of cancer requires cost-effective tools and strategies that enable detection to happen quickly and accurately,” said Fruk. “We designed a test based on peptide-cleaving proteins, which are found at higher levels in the presence of zombie cells, and in turn appear in the early stages of cancer.

“Ultimately, we want to develop a urine test that could help doctors identify signs of the early stages of cancer – potentially months or even years before noticeable symptoms appear.”

As well as targeting lung cancer, Fruk hopes her research, along with joint efforts across other university departments, will result in the development of probes capable of detecting other cancers.

“We have almost completed a functional urine test to detect ‘zombie' cells in lung cancer, which will spot cancer earlier and avoid the need for invasive procedures, but this test does have potential for other cancers,” she said. “Developing more efficient cancer treatments requires earlier detection and better therapies, but also work with other disciplines for a more holistic view of the disease, which is an essential part of my research.”

From uncovering the causes of lung cancer to pioneering drugs to treat it, Cancer Research UK has helped power progress for people affected by lung cancer. Over the last 10 years, the charity has invested over £231 million in lung cancer research.

“Cancer Research UK has played a key role in advancing lung cancer research and improving survival,” said Dr Iain Foulkes, Cancer Research UK’s executive director of research and innovation. “This project being led by Professor Fruk is another example of our commitment to driving progress so that more people can live longer, better lives, free from the fear of cancer.”

Adapted from a Cancer Research UK media release.

Cambridge scientists have developed a urine test for early detection of lung cancer. ̽��ֱ��test, the first of its kind, detects ‘zombie’ cells that could indicate the first signs of the disease.

koto_feja via Getty Images

Close-up of cancer cells

Yes

Landmark 'pill-on-a-thread' cancer screening trial welcomes first participants

cjb250 — Thu, 28 Nov 2024 12:00:02 +0000

A pivotal clinical trial of a 'pill-on-a-thread' test, which will decide if it becomes a new screening programme for oesophageal cancer, has welcomed its first participants.

Inside the institute looking at early cancer

cjb250 — Wed, 24 Jul 2024 07:00:47 +0000

Today sees the launch of the Early Cancer Institute at Cambridge. Its mission is deceptively simple: to detect cancer early enough to cure it.

Cambridge is changing the story of cancer

cjb250 — Mon, 15 Jul 2024 07:00:41 +0000

Find out about groundbreaking cancer research at Cambridge, including our planned new hospital, how we're studying the earliest stages of cancer, how AI is helping fight the disease, and the patients playing a key role in our work.

Ten Cambridge scientists elected as Fellows of the Royal Society 2024

Anonymous — Thu, 16 May 2024 08:51:02 +0000

̽��ֱ��Royal Society is a self-governing Fellowship of many of the world’s most distinguished scientists drawn from all areas of science, engineering and medicine.

̽��ֱ��Society’s fundamental purpose, as it has been since its foundation in 1660, is to recognise, promote and support excellence in science and to encourage the development and use of science for the benefit of humanity.

This year, over 90 researchers, innovators and communicators from around the world have been elected as Fellows of the Royal Society for their substantial contribution to the advancement of science. Nine of these are from the ̽��ֱ�� of Cambridge.

Sir Adrian Smith, President of the Royal Society said: “I am pleased to welcome such an outstanding group into the Fellowship of the Royal Society.

“This new cohort have already made significant contributions to our understanding of the world around us and continue to push the boundaries of possibility in academic research and industry.

“From visualising the sharp rise in global temperatures since the industrial revolution to leading the response to the Covid-19 pandemic, their diverse range of expertise is furthering human understanding and helping to address some of our greatest challenges. It is an honour to have them join the Fellowship.”

̽��ֱ��Fellows and Foreign Members join the ranks of Stephen Hawking, Isaac Newton, Charles Darwin, Albert Einstein, Lise Meitner, Subrahmanyan Chandrasekhar and Dorothy Hodgkin.

̽��ֱ��new Cambridge fellows are:

Professor Sir John Aston Kt FRS

Aston is the Harding Professor of Statistics in Public Life at the Statistical Laboratory, Department of Pure Mathematics and Mathematical Statistics, where he develops techniques for public policy and improves the use of quantitative methods in public policy debates.

From 2017 to 2020 he was the Chief Scientific Adviser to the Home Office, providing statistical and scientific advice to ministers and officials, and was involved in the UK’s response to the Covid pandemic. He was knighted in 2021 for services to statistics and public policymaking, and is a Fellow of Churchill College.

Professor Sarah-Jayne Blakemore FBA FMedSci FRS

Blakemore is the Professor of Psychology and Cognitive Neuroscience, Department of Psychology, and leader of the Developmental Cognitive Neuroscience Group. Her research focuses on the development of social cognition and decision making in the human adolescent brain, and adolescent mental health.

Blakemore has been awarded several national and international prizes for her research, and is a Fellow of the British Academy, the American Association of Psychological Science and the Academy of Medical Sciences.

Professor Patrick Chinnery FMedSci FRS

Chinnery is Professor of Neurology and head of the ̽��ֱ��’s Department of Clinical Neurosciences, and a Fellow of Gonville & Caius College. He was appointed Executive Chair of the Medical Research Council last year, having previously been MRC Clinical Director since 2019.

His principal research is the role of mitochondria in human disease and developing new treatments for mitochondrial disorders. Chinnery is a Wellcome Principal Research Fellow with a lab based in the MRC Mitochondrial Biology Unit and jointly chairs the NIHR BioResource for Translational Research in Common and Rare Diseases. He is a Fellow of the Academy of Medical Sciences.

Professor Rebecca Fitzgerald OBE FMedSci FRS

Fitzgerald is Professor of Cancer Prevention in the Department of Oncology and the inaugural Director of the ̽��ֱ��’s new Early Cancer Institute, which launched in 2022. She is a Fellow of Trinity College.

Her pioneering work to devise a first-in-class, non-endoscopic capsule sponge test for identifying individuals at high risk for oesophageal cancer has won numerous prizes, including the Westminster Medal, and this test is now being rolled out in the NHS and beyond by her spin-out Cyted Ltd.

Professor David Hodell FRS

Hodell is the Woodwardian Professor of Geology and Director of the Godwin Laboratory for Palaeoclimate Research in the Department of Earth Sciences, and a Fellow of Clare College.

A marine geologist and paleoclimatologist, his research focuses on high-resolution paleoclimate records from marine and lake sediments, as well as mineral deposits, to better understand past climate dynamics. Hodell is a fellow of the American Geophysical Union and the American Association for the Advancement of Science. He has received the Milutin Milankovic Medal.

Professor Eric Lauga FRS

Lauga is Professor of Applied Mathematics in the Department of Applied Mathematics and Theoretical Physics, where his research is in fluid mechanics, biophysics and soft matter. Lauga is the author, or co-author, of over 180 publications and currently serves as Associate Editor for the journal Physical Review Fluids.

He is a recipient of three awards from the American Physical Society: the Andreas Acrivos Dissertation Award in Fluid Dynamics, the François Frenkiel Award for Fluid Mechanics and the Early Career Award for Soft Matter Research. He is a Fellow of the American Physical Society and of Trinity College.

Professor George Malliaras FRS

Malliaras is the Prince Philip Professor of Technology in the Department of Engineering, where he leads a group that works on the development and translation of implantable and wearable devices that interface with electrically active tissues, with applications in neurological disorders and brain cancer.

Research conducted by Malliaras has received awards from the European Academy of Sciences, the New York Academy of Sciences, and the US National Science Foundation among others. He is a Fellow of the Materials Research Society and of the Royal Society of Chemistry.

Professor Lloyd Peck FRI FRSB FRS

Peck is a marine biologist at the British Antarctic Survey and a fellow at Wolfson College, Cambridge.

He identified oxygen as a factor in polar gigantism and identified problems with protein synthesis as the cause of slow development and growth in polar marine species. He was awareded a Polar Medal in 2009, the PLYMSEF Silver medal in 2015 and an Erskine Fellowship at the ̽��ֱ�� of Canterbury, Christchurch in 2016-2017.

Professor Oscar Randal-Williams FRS

Randal-Williams is the Sadleirian Professor of Pure Mathematics in the Department of Pure Mathematics and Mathematical Statistics.

He has received the Whitehead Prize from the London Mathematical Society, a Philip Leverhulme Prize, the Oberwolfach Prize, the Dannie Heineman Prize of the Göttingen Academy of Sciences and Humanities, and was jointly awarded the Clay Research Award.

Randal-Williams is one of two managing editors of the Proceedings of the London Mathematical Society, and an editor of the Journal of Topology.

Professor Mihaela van der Schaar FRS

Van der Schaar is the John Humphrey Plummer Professor of Machine Learning, Artificial Intelligence and Medicine in the Departments of Applied Mathematics and Theoretical Physics, Engineering and Medicine.

She is the founder and director of the Cambridge Centre for AI in Medicine, and a Fellow at ̽��ֱ��Alan Turing Institute. Her work has received numerous awards, including the Oon Prize on Preventative Medicine, a National Science Foundation CAREER Award, and the IEEE Darlington Award.

Van der Schaar is credited as inventor on 35 US patents, and has made over 45 contributions to international standards for which she received three ISO Awards. In 2019, a Nesta report declared her the most-cited female AI researcher in the UK.

Ten outstanding Cambridge researchers have been elected as Fellows of the Royal Society, the UK’s national academy of sciences and the oldest science academy in continuous existence.

Royal Society

̽��ֱ��Royal Society in central London

Yes